Literature DB >> 11035901

Pathogenesis of osteoporosis.

C J Rosen1.   

Abstract

Osteoporosis is a very common disorder affecting millions of post-menopausal women and men of various ages. Although the disease is manifested by painful fractures of the spine, hip or radius, the underlying pathogenesis is complex and multifactorial. One of the strongest predictors of future osteoporotic fractures is low bone mineral density. The determinants of adult bone density include the rate of bone acquisition during adolescence and the absolute loss of bone during the six decades of adult life. Recent studies have clarified how bone mass is acquired during the early teen years in both boys and girls. Genetic factors play an enormous role in defining the height of acquisition of bone mass; however, these factors also interact with environmental and hormonal determinants. Many more studies have focused on adult bone loss. Disorders in bone remodelling result in an imbalance in bone turnover, favouring resorption over formation. Systemic factors such as oestrogen deprivation and parathyroid hormone strongly activate remodelling and can, in several circumstances, lead to imbalances in the remodelling cycle. The molecular cues that couple bone formation to resorption have recently been elucidated, and those factors may themselves become therapeutic targets for future treatment regimens to prevent osteoporosis and its resultant fractures. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035901     DOI: 10.1053/beem.2000.0068

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Endocrinol Metab


  14 in total

1.  Bone mineral mass in males and females with and without Down syndrome.

Authors:  Fatima Baptista; Ana Varela; Luis B Sardinha
Journal:  Osteoporos Int       Date:  2004-09-09       Impact factor: 4.507

2.  Idiopathic Juvenile Osteoporosis: A Case Report.

Authors:  Halenur Altan; Gül Tosun; Yaşar Şen
Journal:  J Clin Diagn Res       Date:  2015-08-01

3.  The impact of LRP5 polymorphism (rs556442) on calcium homeostasis, bone mineral density, and body composition in Iranian children.

Authors:  Elham Ashouri; Elham Mahmoodi Meimandi; Forough Saki; Mohammad Hossein Dabbaghmanesh; Gholamhossein Ranjbar Omrani; Marzieh Bakhshayeshkaram
Journal:  J Bone Miner Metab       Date:  2014-12-17       Impact factor: 2.626

Review 4.  Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures.

Authors:  L M McNamara
Journal:  J R Soc Interface       Date:  2009-10-21       Impact factor: 4.118

Review 5.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  Developmental origins of genotype-phenotype correlations in chronic diseases of old age.

Authors:  Shana McCormack; Qianghua Xia; Struan F A Grant
Journal:  Aging Dis       Date:  2012-09-10       Impact factor: 6.745

7.  The effect of LRP5 polymorphisms on bone mineral density is apparent in childhood.

Authors:  M Audrey Koay; Jonathan H Tobias; Sam D Leary; Colin D Steer; Carles Vilariño-Güell; Matthew A Brown
Journal:  Calcif Tissue Int       Date:  2007-05-16       Impact factor: 4.333

Review 8.  Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective.

Authors:  Renqing Zhao
Journal:  Int J Med Sci       Date:  2012-10-27       Impact factor: 3.738

Review 9.  Postmenopausal osteoporosis: the role of immune system cells.

Authors:  Maria Felicia Faienza; Annamaria Ventura; Flaviana Marzano; Luciano Cavallo
Journal:  Clin Dev Immunol       Date:  2013-05-23

10.  Glucose: an energy currency and structural precursor in articular cartilage and bone with emerging roles as an extracellular signaling molecule and metabolic regulator.

Authors:  Ali Mobasheri
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-17       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.